Shares in Vifor and Angion Biomedica hit by trial failure

27 October 2021

Vifor Pharma (VTX: FIFoN) was trading 5% lower at the end of trading on Wednesday, while its partner Angion Biomedica (Nasdaq: ANGN) lost more than 50% of its market value in the first half of the day’s trading in New York.

Earlier, the company had announced that the Phase III trial of Angion’s ANG-3777 did not demonstrate a statistically-significant difference from placebo on the primary endpoint in the population of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF).

"The totality of the DGF data, together with the CSA-AKI data expected later this year, will inform our clinical strategy with respect to ANG-3777"ANG-3777 showed a modest but not statistically-significant difference in estimated glomerular filtration rate (eGFR) of 53.3mL/min/1.73m2 versus 50.4mL/min/1.73m2 for placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK